SCHEMBL337008

SCHEMBL337008

Cn1c(=O)c(C(=O)O)c(O)c2cnc(C(F)(F)F)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.43
ALDH1A1 P00352 5/20 0.33
RXRA P19793 1/20 0.33
NPC1 O15118 5/20 0.33
RAB9A P51151 5/20 0.33
LMNA P02545 3/20 0.33
KDM4E B2RXH2 3/20 0.33
TP53 P04637 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NLRP3 Q96P20 1/20 0.33
MAPT P10636 4/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
FOS P01100 2/20 0.32
JUN P05412 2/20 0.32
NFKB1 P19838 2/20 0.32
NFKB2 Q00653 2/20 0.32
RELA Q04206 2/20 0.32
HPGD P15428 2/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436448 0.86 EGLN1 (0.47) EGLN1RXRANPC1RAB9AMAPT
SCHEMBL336829 0.84 EGLN1 (0.63) EGLN1EGLN2EGLN3
SCHEMBL336505 0.83 ALDH1A1 (0.51) EGLN1ALDH1A1NPC1LMNAKDM4E
SCHEMBL10085742 0.81 EGLN1 (0.48) EGLN1ALDH1A1NPC1RAB9ALMNA
SCHEMBL337546 0.78 EGLN1 (0.50) EGLN1NPC1RAB9AKDM4EKMT2A
SCHEMBL10371375 0.73 KMT2A (0.49) ALDH1A1KDM4EMAPTL3MBTL1KMT2A
SCHEMBL11234096 0.71 KMT2A (0.44) EGLN1ALDH1A1NPC1RAB9ALMNA
SCHEMBL8129315 0.71 KDM4E (0.47) EGLN1ALDH1A1NPC1RAB9ALMNA
SCHEMBL11078500 0.70 FEN1 (0.52) EGLN1ALDH1A1NPC1RAB9ALMNA
SCHEMBL15170445 0.67 FOS (0.32) TP53FOSJUNNFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN EGLN1 4/4885ALDH1A1 108/4885RXRA 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.